Antibiotics: Investors’ Blindspot

Writing for ESG Investor about the health and economic implications of antimicrobial resistance (AMR), Vibeka Mair interviewed Suzi van Es, the Foundation's Investor Engagement Manager. The article also references the Foundation’s work on AMR.

The article highlights the urgent threat of AMR and the importance of investors promoting responsible practices across various industries to tackle this global challenge. Mair discusses initiatives and the critical role of advocating for public policy reform to overcome the economic challenges associated with combating AMR.

Additionally, the article features Suzi's insights into the escalating financial impact of AMR and the numerous factors exacerbating the issue.

"We are seeing overuse [antibiotic] and misuse in healthcare, farming coupled with poor manufacturing and business practices each quietly driving up rising levels of resistance, making the framing of AMR as the silent pandemic, particularly apt."

Mair notes the Foundation’s research on AMR and its efforts to assist investors in addressing it, which includes the evaluations and recommendations laid out in the AMR Benchmark.